OmniAb, Inc. (OABI): Cash & Equivalents

Annual figures by period end, from SEC filings.

$25.52M
As of 2025-12-31
$24.34M
As of 2026-06-30
-8.6%
3-year compound annual growth
$33.39M2021-12-31: $02022-12-31: $33.39M2023-12-31: $16.36M2024-12-31: $27.60M2025-12-31: $25.52M$25.52M
2021-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$25.52M-7.5%2026-03-04, Balance as of period end
2024-12-31$27.60M+68.7%2026-03-04, Balance as of period end
2023-12-31$16.36M-51.0%2025-03-18, Balance as of period end
2022-12-31$33.39Mn/a2024-03-25, Balance as of period end
2021-12-31$0n/a2023-03-30, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
OmniAb, Inc. (OABI)2025-12-31$25.52M-7.5%
Foxo Technologies Inc. (FOXO)2025-12-31$207.5K+203.9%
MaxCyte, Inc. (MXCT)2025-12-31$20.07M-28.0%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.45M+483.5%
Absci Corp (ABSI)2025-12-31$20.02M-51.4%
NRC Health (NRC)2025-12-31$4.14M-2.2%
iSpecimen Inc. (ISPC)2025-12-31$6.88M+266.3%
OneMedNet Corp (ONMD)2025-12-31$585.0K+240.1%
Medpace Holdings, Inc. (MEDP)2025-12-31$497.05M-25.8%

Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗